Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by jammer4444on Jul 11, 2017 3:03pm
111 Views
Post# 26456845

United States

United StatesLooks like things are going well in the US.

IRIS recently raised lots of money (well over $4 million, probably closer to $10 million):

https://ballastpointventures.com/2017/06/bpv-invests-in-pensacola-based-intelligent-retinal-imaging-systems/

IRIS is active in 28 states.  Even AthenaHealth is using IRIS:

https://www.athenahealth.com/healthcare-technology-partners/clinical-device-integration/intelligent-retinal-imaging-systems

Diagnos signed a licensing agreement with IRIS in 2012, with a 3-year term, but there was no update after that.

In 2012, the press release said:

Intelligent Retina Imaging Systems (IRIS) will pay DIAGNOS $700,000 over a three year period. "We believe that our IRIS model, using CARA, is an excellent solution in helping to prevent vision loss in the diabetic population. We have the ability to preserve the vision of most, if not all, diabetic patients if we can treat them at the appropriate time." said Dr Sunil Gupta, President of IRIS.


If anyone knows about licensing agreements, I would like to hear their thoughts.
Bullboard Posts